<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588389</url>
  </required_header>
  <id_info>
    <org_study_id>H00016236</org_study_id>
    <nct_id>NCT04588389</nct_id>
  </id_info>
  <brief_title>Comparison of Quadratus Lumborum Block Types</brief_title>
  <official_title>Comparison of Quadratus Lumborum Block With Medical Management for Pain Control After Lumbar Spine Fusion Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eman Nada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the quality of analgesia and reduction of opioid use, between&#xD;
      standard of care and two groups of local anesthetic blocks in different location in the&#xD;
      quadratus lumborum plane, for postoperative pain control after lumbar spinal fusion and if it&#xD;
      reduces opioid consumption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a pilot study as part of planning for a larger randomized controlled trial. The&#xD;
      study plans to enroll a total of 30 patients, with 10 patients randomly assigned in each&#xD;
      group of the study. Group I will receive the standard of care multimodal pharmacological&#xD;
      management. Group II will receive standard of care multimodal pharmacological management plus&#xD;
      the Quadratus Lumborum II local anesthetic block. Group III will receive standard of care&#xD;
      multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block.&#xD;
      Measurements of opioid use, pain, and side effects will be recorded for each patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>We will randomize 10 patients into one of three groups for a total of 30 patients. Each patient will be longitudinally followed until discharge.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>For the blinding purposes, the patients will be told that there are two possible sites at which they will receive the block. The sites will be either in the operating room before you wake up from anesthesia or in the post-anesthesia care unit (PACU). The patients on the medical management group will be told that they have received their block before recovering from anesthesia, the PACU nurse will be told the same as well to make him or her blinded as a pain assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>12 hours</time_frame>
    <description>Dose of the opioids consumed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Dose of the opioids consumed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>36 hours</time_frame>
    <description>Dose of the opioids consumed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>48 hours</time_frame>
    <description>Dose of the opioids consumed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>0 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>1 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>6 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>12 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>18 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>24 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>30 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>36 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>42 Hours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>48ours</time_frame>
    <description>Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge Opioid Use</measure>
    <time_frame>2 weeks</time_frame>
    <description>The amount of left-over opioid pills at 2 weeks in the follow up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>Up to 1 week</time_frame>
    <description>The presence of any side effects reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pain</condition>
  <condition>Opioid Use</condition>
  <condition>Lumbar Disc Herniation</condition>
  <arm_group>
    <arm_group_label>Group 1 Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group I will receive the standard of care multimodal pharmacological management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Standard of Care + Quadratus Lumborum Block II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Standard of Care + Quadratus Lumborum Block III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection Location 1</intervention_name>
    <description>Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1</description>
    <arm_group_label>Group 2 Standard of Care + Quadratus Lumborum Block II</arm_group_label>
    <other_name>Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection Location 2</intervention_name>
    <description>Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2</description>
    <arm_group_label>Group 2 Standard of Care + Quadratus Lumborum Block III</arm_group_label>
    <other_name>Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multimodal Pharmacological Management</intervention_name>
    <description>standard of care multimodal pharmacological management</description>
    <arm_group_label>Group 1 Standard of Care</arm_group_label>
    <arm_group_label>Group 2 Standard of Care + Quadratus Lumborum Block II</arm_group_label>
    <arm_group_label>Group 2 Standard of Care + Quadratus Lumborum Block III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Patients undergoing lumbar spinal fusion surgery.&#xD;
&#xD;
          -  Patients from 40-80 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent drug abuse&#xD;
&#xD;
          -  History of illicit drug use&#xD;
&#xD;
          -  Chronic pain patients not related to the back lesions.&#xD;
&#xD;
          -  Opioid tolerant patients.&#xD;
&#xD;
          -  Patients with any lower extremity weaknesses or deficits.&#xD;
&#xD;
          -  Patients with American Society of Anesthesiologists (ASA) classification more than 3.&#xD;
&#xD;
          -  Coagulopathy.&#xD;
&#xD;
          -  Infection near or in the area of the block.&#xD;
&#xD;
          -  Pregnant patients.&#xD;
&#xD;
          -  Uncooperative patients who refuse care which directly effects research participation&#xD;
             or clinical care.&#xD;
&#xD;
          -  If the surgeon reports performing non-typical fusion.&#xD;
&#xD;
          -  The presence of intraoperative complications like nerve injury or abnormal results of&#xD;
             neuromonitoring and extensive dissection.&#xD;
&#xD;
          -  Vulnerable populations (prisoner, mental impairment / dementia, pregnant, etc.)&#xD;
&#xD;
          -  Subjects on chronic buprenorphine therapy (either for opioid replacement or pain&#xD;
             control)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eman Nada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan M DeWolf, MS</last_name>
    <phone>9783021857</phone>
    <email>ryan.dewolf@umassmed.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan M DeWolf, ms</last_name>
    <phone>7743032649</phone>
    <email>ryan.dewolf@umassmemorial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMASS Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Eman Nada</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Lumbar Spine</keyword>
  <keyword>Nerve Block</keyword>
  <keyword>Opioid Use</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data with other researchers. However, results of the study will be shared through publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

